SciSparc Ltd. (SPRC) Stock Price & Analysis
SciSparc Ltd. (SPRC) closed at USD 1.09 on Friday, October 23, 2026, down 9.17% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.2; the Oct 23, 2026 session ranged USD 1.07–1.21 on volume of 207,011 shares. Market capitalization is $633,260, with a 52-week range of USD 1.07–35.47 (NCM). Source: Nexqual, retrieved October 25, 2026 at 09:04 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SPRC.md
Key facts (SPRC)
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $5K; 1 not under a Rule 10b5-1 plan ($5K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: None.
- Total return with dividends: 1Y -97.0% vs S&P 500 +13.4%; 5Y -100.0% vs S&P 500 +76.9%.
Insider sales (SEC Form 4, open-market, last ~7 months) (SPRC)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Shrem Itschak | Director | 462 | $5K | 4.2% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (SPRC)
Consensus None.
Total return (dividends reinvested) (SPRC)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -97.0% | -100.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -97.0% | -87.2% |
| Volatility (annualized) | 169.2% | 144.7% |
| Max drawdown | -97.0% (Oct 2025→Oct 2026) | -100.0% (Nov 2021→Oct 2026) |
SPRC suppliers, customers and competitors (named in its 20-F)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | FedEx (FDX) | “the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services” |
| Supplier | UPS (UPS) | “the customer depends on third parties outside of our control, including suppliers and logistics providers such as FedEx, UPS, postal services” |
| Customer | SciSparc Nutraceuticals | “of SciSparc Nutraceuticals to acquire or retain customers, and our efforts to sell new products or increase sales of our existing products,” |
| Customer | Meta Platforms (META) | “Our customers may engage with us online through our social media platforms, including Facebook and Instagram,” |
| Partner | Clearmind Medicine Inc. (CMND) | “For example, our collaboration with Clearmind Medicine Inc.,” |
| Partner | Polyrizon Ltd. (PLRZ) | “In addition, in August 2024, we entered into an exclusive patent license agreement with Polyrizon Ltd.,” |
| Partner | Amazon (AMZN) | “such as Amazon, which may result in an online retail partner removing the product from its marketplace.” |
| Partner | Capital Point and Evero Health | “pursuant to a joint venture transaction entered into on May 15, 2020 by and between us, Capital Point and Evero Health Ltd. one of our” |
| Partner | AutoMax Motors | “the Israeli Police and the arrest of senior officials of AutoMax, we entered into a framework agreement with AutoMax on October 6, 2025” |
| Partner | Miza III Ventures | “into a definitive asset and share purchase agreement with Miza, a publicly traded company listed on the TSXV, pursuant to which we agreed” |
| Partner | Nexentis Technologies Inc. (NXTS) | “a securities purchase and exchange agreement with Nexentis Technologies Inc. ("Nexentis", formerly known as "N2OFF,” |
Quoted from the company's 20-F filed Apr 29, 2026.
Companies that name SPRC in their SEC reports
| Relationship to SPRC | Company | Filing | Sentence |
|---|---|---|---|
| partner | Nexera Technologies Ltd (NEXR) | 20-F Apr 1, 2026 | “services are provided in collaboration with SciSparc.” |
| partner | Polyrizon Ltd. (PLRZ) | 20-F Mar 25, 2026 | “August 13, 2024, we entered into an exclusive patent license agreement, or the SciSparc License Agreement, with SciSparc Ltd., or SciSparc,” |
| partner | Clearmind Medicine Inc. (CMND) | 20-F Jan 20, 2026 | “ongoing collaboration with SciSparc, we entered into a research agreement with the Hebrew University of Jerusalem to evaluate our and” |
SPRC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Dec 2024) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 25, 2026 at 09:04 UTC)
| Price | USD 1.09 |
|---|---|
| Change | ▼ 9.17% (down) |
| Previous Close | USD 1.2 |
| Open | USD 1.21 |
| Day Range | USD 1.07 – 1.21 |
| 52-Week Range | USD 1.07 – 35.47 |
| Volume | 207,011 shares |
| Market Cap | $633,260 |
| Exchange | NCM |
Technical Analysis (SPRC)
Nexqual's technical model rates SPRC "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 25, 2026 at 09:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 14.21 (oversold) |
| vs SMA50 | Below (USD 4.75) |
| MACD | -1.05 (negative) |
Analyst Ratings (SPRC)
Wall Street analysts rate SPRC "None", per Nexqual as of October 25, 2026 at 09:04 UTC.
| Consensus Rating | None |
|---|
Earnings (SPRC)
Source: Nexqual, October 25, 2026 at 09:04 UTC.
Financials & Fundamentals (SPRC)
| Total Revenue | $679,000 |
|---|---|
| Revenue Growth (latest quarter, YoY) | -38.40% |
| Gross Margin | +950.81% |
| Operating Margin | -1720.78% |
| Profit Margin | +0.00% |
| ROE | -164.49% |
| Debt / Equity | 0.24 |
| Current Ratio | 0.87 |
| Total Cash | $4.44M |
| Total Debt | $2.68M |
Source: Nexqual, October 25, 2026 at 09:04 UTC.
Financial Health Score (SPRC)
Nexqual rates SciSparc Ltd.'s overall financial health "Weak" across five dimensions, as of October 25, 2026 at 09:04 UTC.
| Growth | Critical — Revenue -38% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $4M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$6M (TTM) |
| Efficiency | Critical — ROE -164%, ROA -26.0% |
Ownership (SPRC)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +9.27% |
| Shares Outstanding | 580,973 |
| Float | 561,121 |
| Short % of Float | +1.96% |
Source: Nexqual, October 25, 2026 at 09:04 UTC.
Leadership (SPRC)
SciSparc Ltd. is led by Oz Adler, CEO & CFO, per Nexqual as of October 25, 2026 at 09:04 UTC.
| CEO & CFO | Oz Adler |
|---|---|
| President & Director | Amitai Weiss |
Major Backers & Investors (SPRC)
Notable institutional backers of SciSparc Ltd. include HRT Financial LP, Jane Street Group, LLC, Citadel, according to Nexqual as of October 25, 2026 at 09:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HRT Financial LP | 3.75% |
| Jane Street Group, LLC | 2.92% |
| Citadel | 1.96% |
| UBS Group AG | 0.8% |
Source: Nexqual, October 25, 2026 at 09:04 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 25, 2026 at 09:04 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt